A WINDFALL IN THE BOARDROOM:
The $1.7-billion GlaxoSmithKline offer dramatically boosts the share holdings of key ID Biomedical executives. Here's what some of their holdings were worth Wednesday at $35 a share.*
CEO Anthony Holler
522,934 shares = $18.3 million
Director Daniel Carriere
238,900 shares = $8.36 million
President Todd Patrick
160,030 shares = $5.6 million
Chairman Richard Bastiani
103,858 shares = $3.63 million
*Source: Bloomberg holdings search, filings range from April to July, 2005
THE START OF A BILLION-DOLLAR FIRM:
- 1991 Frank and Tony Holler, with other shareholders, found ID Biomedical as a spinoff comany from the University of British Columbia. Their business is developing a gene-based test to diagnose tuberculosis.
- 1992 ID Biomedical launches an initial public offering on the former Vancouver Stock Exchange.
- 1993 In August, ID Biomedical shares begin trading on the NASDAQ exchange in the U.S.
- 1995 ID Biomedical shares leave the VSE and list on the Toronto Stock Exchange
- 1999 ID Biomedical shifts focus, abandons gene-based diagnostics and zeroes in on the vaccine business. It has 30 employees and a market capitalization of $48 million.
- 2001 In May, ID Biomedical acquires the Montreal-based vaccine developer Intellivax, which gives it the key product Fluinsure and the Proteozome nasal-delivery technology.
- 2004 ID Biomedical acquires vaccine-maker Shire Pharmaceuticals for $120 million US putting it in the manufacturing business. By the end of 2004, the company has 458 full-time employees and is worth more than $877 million.
- 2005 In September, ID Biomedical is taken over in a $1.7 billion US purchase by United-Kindom-based vaccine giant GlaxoSmithKline.
I added..
- 2006 Frank and his crew become board members of RBM.. Is gene-based tests on the horizon???
...
Taken from...
uilo.ubc.ca{4587077B-29BC-4C15-A090-AEEB2C103540}}
stockhouse.com
ctv.ca |
